FDA Official Offers Agency's Take on Protein IVDMIA Mock 510(k) Submissions

Attention to assay reproducibility and selection of appropriate intended use populations will be key to the success of proteomics-based tests, FDA staff fellow Joshua Levin suggested at a talk this week discussing the agency's review of two mock submissions for protein IVDMIAs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.